Preclinical and Phase I/II Trials of AAV-AAT Vectors: Phase I Trial of Intramuscular Injection of a Recombinant Adeno-Associated Virus Alpha 1-Antitrypsin (rAAV1-CB-hAAT) Gene Vector to AAT-Deficient Adults
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2016
Price : $35 *
At a glance
- Drugs AGTC 0106 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 05 May 2016 Results published in the media release from American Society of Gene Therapy.
- 05 May 2016 According to a media release from American Society of Gene Therapy, results from this trial were presented in a podium session at the American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting.